Clinical Trials
32 trialsPembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
CurbMF
Virogen Biotechnology Inc.
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin Co., Ltd.
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Kyowa Kirin Co., Ltd.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Emory University
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Kyowa Kirin Co., Ltd.
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Kyowa Kirin Co., Ltd.
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Kyowa Kirin Co., Ltd.
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Kyowa Kirin Co., Ltd.
MOGAT
European Organisation for Research and Treatment of Cancer - EORTC
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Pfizer
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Aichi Medical University
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Kyowa Kirin Co., Ltd.